Page 7 - பிராங்க்ஃபர்ட் ப்ரைம் தரநிலை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

U S Centers for Medicare & Medicaid Services publish negative NCD for Epi proColon

Epigenomics AG / Key word(s): Miscellaneous U.S. Centers for Medicare & Medicaid Services publish negative NCD for Epi proColon 20-Jan-2021 / 00:02 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. U.S. Centers for Medicare & Medicaid Services publish negative NCD for Epi proColon Berlin, January 19, 2021 - Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the Company ) announces that the U.S. Centers for Medicare & Medicaid Services (CMS) have issued a negative reimbursement decision in connection with the National Coverage Determination (NCD) of Epi proColon, Epigenomics blood test for colorectal cancer screening. The Company is currently evaluating options for an appeal, litigation and/or other alternatives to achieve Medicare coverage.

Us centers for medicare medicaid servicesNational coverage determinationMedicaid servicesFrankfurt prime standardFrederic hilkeஎங்களுக்கு மையங்கள் க்கு மருத்துவ மருத்துவ உதவி சேவைகள்தேசிய பாதுகாப்பு உறுதியைமருத்துவ உதவி சேவைகள்பிராங்க்ஃபர்ட் ப்ரைம் தரநிலை

QIAGEN N V : QIAGEN Plans to Resubmit EUA Submission in the U S for QIAreach SARS-CoV-2 Antigen Test in the First Quarter of 2021

(2) QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it plans to resubmit in the first quarter of 2021 its QIAreach SARS-CoV-2 Antigen Test to the U.S. Food and Drug Administration for Emergency Use Authorization to detect SARS-CoV-2 antigens in people with active infections in 15 minutes. This comes after QIAGEN decided to proactively withdraw the first submission made in November 2020 for this product to address a chemistry-related issue. QIAGEN believes it has resolved the issue, and data is now being collected for submission to the FDA. The eHub used to read out test results is not affected.

Thierry bernardRobert reitzeJohn gilardiThomas theuringerPhoebe lohDrug administration for emergency use authorizationFrankfurt prime standardDrug administrationEmergency use authorizationChief executive officerதியரி பெர்னார்ட்ஃபோப் லோபிராங்க்ஃபர்ட் ப்ரைம் தரநிலைஅவசரம் பயன்பாடு அங்கீகாரம்தலைமை நிர்வாகி அதிகாரி

QIAGEN N V : QIAGEN Confirms Effectiveness of Its SARS-CoV-2 PCR Tests in the Face of Mutations of the Coronavirus

QIAGEN N.V.: QIAGEN Confirms Effectiveness of Its SARS-CoV-2 PCR Tests in the Face of Mutations of the Coronavirus QIAGEN started cross-checking variants in May 2020 and continues to conduct biweekly assessments QIAseq SARS-CoV-2 Primer Panel helps with sequencing RNA and identifying mutations QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its polymerase chain reaction (PCR) tests remain accurate and effective in detecting SARS-CoV-2 infections and will continue to closely monitor their performance as global concerns mount regarding the detection of new viral variants by established testing methods. QIAGEN has successfully assessed its SARS-CoV-2 PCR tests against genetic mutations of the virus uploaded to the GISAID and GenBank public databases since May 2020. A latest round of assessments conducted in January 2021 again confirmed that no recorded mutations affected the sensitivity of QIAGEN assays for detection of SARS-CoV-2. Surveillance of genetic

South africaUnited kingdomRobert reitzeJohn gilardiDavide manisseroThomas theuringerPhoebe lohPrimer panelFrankfurt prime standardChief medical officer infectionImmune diagnosticsCorona virusஒன்றுபட்டது கிஂக்டம்ஃபோப் லோப்ரைமர் குழுபிராங்க்ஃபர்ட் ப்ரைம் தரநிலை

Qiagen N : Underlines and Innovates Its Commitment to Sustainability With a EUR 400mn Sustainability-linked Credit Facility

Qiagen N : Underlines and Innovates Its Commitment to Sustainability With a EUR 400mn Sustainability-linked Credit Facility
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Unicredit bankDeutsche bankFrankfurt prime standardRoland sackersChief financial officerFacility agentடாய்ச் வங்கிபிராங்க்ஃபர்ட் ப்ரைம் தரநிலைதலைமை நிதி அதிகாரி

QIAGEN N V : QIAGEN Underlines and Innovates Its Commitment to Sustainability With a EUR 400mn Sustainability-linked Credit Facility

QIAGEN N.V.: QIAGEN Underlines and Innovates Its Commitment to Sustainability With a EUR 400mn Sustainability-linked Credit Facility Transaction was well received and significantly oversubscribed by eleven banks QIAGEN will donate margin gains of improved ESG rating to sustainability-linked causes QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard QIA) announced today that it has successfully concluded a syndicated revolving credit facility for EUR 400mn with an interest rate linked to the company s environmental, social and governance (ESG) performance. The agreement makes QIAGEN the first provider of molecular diagnostics solutions with a sustainability component built into corporate borrowing. It underlines QIAGEN s commitment to people and planet by creating financial incentives to further integrate sustainability throughout every part of its business.

Robert reitzeJohn gilardiThomas theuringerPhoebe lohUnicredit bankHead of external communicationsCorporate communicationsDeutsche bankFrankfurt prime standardRoland sackersChief financial officerFacility agentPresident corporate communicationsInvestor relationsExternal communicationsManager public relations